Related Experiment Video

Updated: Jul 7, 2026

Guidelines for Elective Pediatric Fiberoptic Intubation
11:19

Guidelines for Elective Pediatric Fiberoptic Intubation

Published on: January 17, 2011

Anesthetic management of children with pulmonary arterial hypertension

Robert H Friesen1, Glyn D Williams

  • 1Department of Anesthesia, Children's Hospital, Aurora, CO 80045, USA. Friesen.Robert@tchden.org

Paediatric Anaesthesia
|January 31, 2008
PubMed

Insights

Anesthetic management for pulmonary arterial hypertension (PAH) requires careful consideration of hemodynamic stability. Anesthesiologists must balance surgical needs with minimizing pulmonary vascular resistance (PVR) and cardiac dysfunction to prevent crises.

Area of Science:

  • Anesthesiology
  • Cardiology
  • Pediatrics

Background:

  • Pulmonary arterial hypertension (PAH) presents significant perioperative risks, including pulmonary hypertensive crisis and cardiac arrest.
  • Hemodynamic deterioration in PAH patients can result from increased pulmonary vascular resistance (PVR), impaired ventricular function, and coronary hypoperfusion.

Purpose of the Study:

  • To outline anesthetic management strategies for pediatric patients with PAH.
  • To emphasize the importance of understanding PAH pathophysiology and potential anesthetic complications.

Main Methods:

  • Review of anesthetic implications in PAH patients.
  • Discussion of anesthetic drug effects on PVR and myocardial function.
  • Integration of pulmonary vasodilator therapy into anesthetic plans.

Main Results:

  • Anesthetic drugs have variable effects on PVR, necessitating cautious selection.
  • Balanced anesthetic management aims to maintain adequate anesthesia while minimizing PVR increases and cardiac depression.
  • Advances in pulmonary vasodilators offer improved medical therapy for PAH.

Conclusions:

  • Anesthesiologists must be aware of the heightened perioperative risks in children with PAH.
  • Developing an appropriate anesthetic plan and preparedness for managing pulmonary hypertensive crises are crucial.
  • Comprehensive understanding of PAH pathophysiology is essential for safe patient care.

Related Concept Videos

Parenteral Anesthetics: Overview01:24

Parenteral Anesthetics: Overview

Intravenous anesthetics are drugs administered parenterally to induce anesthesia or sedation. Propofol is a widely used agent formulated as a 1% emulsion in soybean oil, glycerol, and egg phosphatide. It induces rapid anesthesia primarily due to its rapid distribution from the bloodstream to target tissues and is metabolized in the liver. However, it can cause significant pain on injection and hypertriglyceridemia. Fospropofol, a water-based prodrug of propofol, lacks these adverse effects.
Inhalational Anesthetics: Overview01:20

Inhalational Anesthetics: Overview

Inhalation anesthetics are drugs that induce general anesthesia upon inhalation. They work by increasing the sensitivity of GABAA receptors or inhibiting NMDA receptors, leading to a decrease in central nervous system activity. The depth of anesthesia can be rapidly adjusted by changing the concentration of the inhaled gas. Some common examples of inhalational anesthetics include volatile liquids like isoflurane, desflurane, sevoflurane and gases like xenon and nitrous oxide. Isoflurane, a...
General Anesthesia: Overview01:24

General Anesthesia: Overview

Anesthesia is a medical procedure that uses drugs for CNS suppression to enable painless surgeries and procedures. The selection of anesthetics is influenced by their pharmacokinetic properties, side effects, and patient characteristics. Various types of anesthesia include general, local, regional, spinal, and inhalational.
General anesthesia induces unconsciousness in the whole body, while the others target specific areas or sensations. It is administered to minimize adverse effects, maintain...
Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists01:18

Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists

Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme (ECE). Of...
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure01:16

Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure

Oxygen therapy has emerged as a significant tool in enhancing the quality of life for patients suffering from pulmonary arterial hypertension (PAH). While this therapy has principally been studied on patients with significant hypoxemia, this therapeutic approach helps prevent potential organ damage and can be administered in the comfort of one's home.
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue, improving...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...